Insurance-Driven Switches to Adalimumab Biosimilars Maintain Disease Control in Pediatric Inflammatory Bowel Disease
Insurance-Driven Switches to Adalimumab Biosimilars Maintain Disease Control in Pediatric Inflammatory Bowel Disease https://pediatricsnationwide.org/wp-content/uploads/2021/10/AdobeStock_71020796-1024x683.jpg 1024 683 Pam Georgiana https://pediatricsnationwide.org/wp-content/uploads/2023/07/May-2023.jpg
New pediatric data may help clinicians reassure patients and families about nonmedical treatment switches Since biosimilar versions of adalimumab became available in the United States in 2023, more insurers have required patients receiving the originator medication to switch to a biosimilar. Researchers have deemed biosimilars safe and effective alternatives in adults. However, there is limited…